Xeltis has secured nearly €50m of new financing, consisting of up to €37.5m from the European Investment Bank (EIB), supported under the European Commission’s Invest EU programme, and €10m from existing investors, including EQT, investing from its LSP Health Economics Fund 2, and Invest-NL.
The proceeds raised will be used to advance aXess, its restorative vascular access conduit, into commercialisation, including upscaling production and hiring, and supporting the continued development of its broader pipeline.
The financing follows the announcement of clinical data from Xeltis’ EU pivotal trial investigating the patency, safety, and performance of aXess in adult patients with end-stage renal disease requiring vascular access to start or maintain haemodialysis therapy.
The study successfully met its primary endpoints, demonstrating sustained patency rates and significant improvements across all key measures, such as reduced infection rates and fewer interventions, compared to standard of care. A US pivotal trial for aXess is also underway, and is heading towards premarket approval, with interim data expected in 2026.
Eliane Schutte, chief executive officer, Xeltis, commented: “We are deeply grateful for the continued support of the EIB and our existing investors and proud of the confidence they have shown in Xeltis at this key moment for the company. The EU pivotal trial for aXess has delivered exceptional data, and with this new financing, we now have both the validation and resources to move forward toward commercialisation. We are now looking to expand our production facilities and hire the critical staff that we will need to bring aXess to the market and transform vascular access treatment for haemodialysis patients.”
Robert de Groot, vice president, European Investment Bank, said: “Xeltis is at the cutting-edge of their field, directly contributing to improved outcomes for dialysis and cardiovascular patients. As such, we are proud to back Xeltis with €37.5m of venture debt, helping it move from breakthrough science to real world treatment across Europe. This partnership shows how targeted European innovation investment accelerates medical progress and strengthens Europe’s MedTech leadership.”
Alexander Goemans, chief financial officer, Xeltis, added: “The EIB is a valued partner for Xeltis and we sincerely appreciate their ongoing support. Momentum is building rapidly, and the EIB’s commitment, along with the continued support of our existing investors, provides a strong foundation for Xeltis to move confidently towards commercialisation.”
The financing will also be used to further develop Xeltis’ broader pipeline of transformative implants, developed using Xeltis’ proprietary Endogenous Tissue Restoration (ETR) platform technology, which incorporates Nobel-prize winning breakthroughs in PFAS free polymer technology.
Xabg, Xeltis’ coronary artery bypass conduit and second product in clinical development, has demonstrated positive 24-month follow-up results. Xeltis is also making significant progress across other indications in its pipeline, it said in a press release.
